Merck & Co to expand in India, favourable IPR ruling encourages co to invest more
The Delhi High Court decision on its anti-diabetes drug Januvia is among the factors encouraging Merck to invest in India, global CEO Kenneth Frazier told ET. (Source: The Economic Times Healthcare and Biotech News)
Source: The Economic Times Healthcare and Biotech News - November 5, 2015 Category: Pharmaceuticals Source Type: news

Sitagliptin vs Mitiglinide Switched From Insulin in T2DSitagliptin vs Mitiglinide Switched From Insulin in T2D
A new study examines the feasibility and efficacy of substituting these oral hypoglycemic agents for insulin therapy in patients with type 2 diabetes. BMJ Open Diabetes Research & Care (Source: Medscape Today Headlines)
Source: Medscape Today Headlines - October 28, 2015 Category: Consumer Health News Tags: Diabetes & Endocrinology Journal Article Source Type: news

Merck's once-weekly diabetes drug found effective in study
(Reuters) - Merck & Co said its experimental once-weekly diabetes drug was found to be as good as its blockbuster Januvia, which is taken once a day. (Source: Reuters: Health)
Source: Reuters: Health - September 16, 2015 Category: Consumer Health News Tags: healthNews Source Type: news

Merck’s Omarigliptin, an Investigational Once-Weekly DPP-4 Inhibitor, Achieved Similar A1C Reductions to JANUVIA® (sitagliptin) in Patients with Type 2 Diabetes Inadequately Controlled on Metformin Monotherapy
Dateline City: KENILWORTH, N.J. KENILWORTH, N.J.--(BUSINESS WIRE)--Merck (NYSE:MRK), known as MSD outside the United States and Canada, today announced that omarigliptin, Merck’s investigational once-weekly DPP-4 inhibitor in development for adults with type 2 diabetes, achieved its primary efficacy endpoint in a Phase 3 study. Omarigliptin was found to be non-inferior to Merck’s once-daily DPP-4 inhibitor, JANUVIA® (sitagliptin), at reducing patients’ A1C* levels from baseline, with similar A1C reductions achieved in ...
Source: Merck.com - Research and Development News - September 16, 2015 Category: Pharmaceuticals Tags: Research and Development News Corporate News Latest News Source Type: news

The Efficacy, Safety of Sitagliptin in the Elderly With T2DThe Efficacy, Safety of Sitagliptin in the Elderly With T2D
Treatment with the DPP-4 inhibitor sitagliptin may be a safe and effective therapeutic option for elderly patients with type 2 diabetes. BMC Endocrine Disorders (Source: Medscape Today Headlines)
Source: Medscape Today Headlines - September 4, 2015 Category: Consumer Health News Tags: Diabetes & Endocrinology Journal Article Source Type: news

TECOS Subanalysis: No Heart-Failure Risk With Sitagliptin (Januvia)TECOS Subanalysis: No Heart-Failure Risk With Sitagliptin (Januvia)
In this prespecified analysis, investigators found absolutely no heart-failure signal with sitagliptin, leaving researchers to suggest the agent and its "clean" safety profile should be preferred over other DPP-4 inhibitors. Heartwire from Medscape (Source: Medscape Medical News Headlines)
Source: Medscape Medical News Headlines - September 1, 2015 Category: Consumer Health News Tags: Cardiology News Source Type: news

FDA warns of severe joint pain risk with DPP-4 diabetes drugs
(Reuters) - A class of diabetes drugs that include Merck & Co Inc's Januvia has been linked with severe joint pain, the U.S. Food and Drug Administration said on Friday. (Source: Reuters: Health)
Source: Reuters: Health - August 28, 2015 Category: Consumer Health News Tags: healthNews Source Type: news

Slow Medicine: Januvia Won't Kill You
(MedPage Today) -- But it still doesn't improve cardiovascular outcomes (Source: MedPage Today Endocrinology)
Source: MedPage Today Endocrinology - August 27, 2015 Category: Endocrinology Source Type: news

New Analyses from the IMPROVE-IT Outcomes Study of VYTORIN® (ezetimibe and simvastatin) and the TECOS Cardiovascular Safety Trial of JANUVIA® (sitagliptin) Will Be Presented at the European Society of Cardiology Congress
Dateline City: KENILWORTH, N.J. Additional Real-World Analyses from DYSIS and DYSIS II Assessing the Treatment of Dyslipidemia to be Presented KENILWORTH, N.J.--(BUSINESS WIRE)--Merck (NYSE:MRK), known as MSD outside the United States and Canada, announced today that new analyses from the investigational IMPROVE-IT (IMProved Reduction of Outcomes: VYTORIN Efficacy International Trial) study of VYTORIN® (ezetimibe and simvastatin), the TECOS (Trial Evaluating Card...
Source: Merck.com - Product News - August 20, 2015 Category: Drugs & Pharmacology Tags: Prescription Medicine News Research and Development News Corporate News Latest News Source Type: news

Hayward-made diabetes treatment beats $6B Merck drug in head-to-head trial
A drug for type 2 diabetes that's manufactured in Hayward showed its tiny drug pump worked better in a head-to-head comparison with the leading once-a-day pill for the disease, Januvia, which generated more than $6 billion in revenue last year. Intarcia, a privately-held firm based in Boston's Seaport District, said the trial showed patients who had its tiny ITCA 650 implanted under their skin saw double the reduction in a type of hemoglobin tied to the disease after one year than patients taking… (Source: bizjournals.com Health Care:Pharmaceuticals headlines)
Source: bizjournals.com Health Care:Pharmaceuticals headlines - August 19, 2015 Category: Pharmaceuticals Authors: Don Seiffert Source Type: news

MassDevice.com +3 | The top 3 medtech stories for August 19, 2015
Say hello to MassDevice +3, a bite-sized view of the top three medtech stories of the day. This feature of MassDevice.com’s coverage highlights our 3 biggest and most influential stories from the day’s news to make sure you’re up to date on the headlines that continue to shape the medical device industry.   3. Masimo takes over Tony Stark’s headquarters Masimo moved its headquarters to a Hollywood-hotspot at 52 Discovery in Irvine, Calif., a location often used in films to represent upscale corporate headquarters. The rotund glass front entrance has served as a backdrop for multiple Hollywood ...
Source: Mass Device - August 19, 2015 Category: Medical Equipment Authors: MassDevice Tags: Blog Plus 3 Source Type: news

Diabetes: Intarcia’s implantable drug pump tops Merck’s Januvia
Intarcia Therapeutics yesterday unveiled top-line results from a year-long trial of an implantable drug pump for Type II diabetics, saying its ITCA 650 treatment proved superior to its comparator, Merck‘s (NYSE:MRK) Januvia. Fifty-two week results from the Phase III Freedom-2 trial met all primary and secondary endpoints, “demonstrating superiority over Januvia at every measured time point,” Intarcia said. The matchstick-sized, miniature osmotic pump reduced glycated hemoglobin (HbA1c) levels and weight in patients in the study, the company said. The subcutaneous ITCA 650 is designed to deliver the ...
Source: Mass Device - August 19, 2015 Category: Medical Equipment Authors: Brad Perriello Tags: Clinical Trials Diabetes Drug Pumps Intarcia Therapeutics newtag Source Type: news

Intarcia's Diabetes Treatment Clears Key Test
Closely held Intarcia Therapeutics said its implantable drug-delivery pump proved superior to Merck’s top-selling drug Januvia in helping diabetes patients control blood sugar in a head-to-head clinical trial. (Source: WSJ.com: Health)
Source: WSJ.com: Health - August 19, 2015 Category: Pharmaceuticals Tags: FREE Source Type: news

Boston firm’s diabetes treatment beats $6B Merck drug in head-to-head trial
A Boston company says that a trial of 535 patients with type 2 diabetes showed its tiny drug pump worked better in a head-to-head comparison with the leading once-a-day pill for the disease, Januvia, which generated more than $6 billion in revenue last year. Intarcia, a privately-held firm based in the Seaport District, said the trial showed patients who had its tiny ITCA 650 implanted under their skin saw double the reduction in a type of hemoglobin tied to the disease after one year than patients… (Source: bizjournals.com Health Care:Pharmaceuticals headlines)
Source: bizjournals.com Health Care:Pharmaceuticals headlines - August 19, 2015 Category: Pharmaceuticals Authors: Don Seiffert Source Type: news

Sitagliptin vs. Sulfonylureas in Elderly Patients With T2DMSitagliptin vs. Sulfonylureas in Elderly Patients With T2DM
Sulfonylureas are commonly used to treat T2DM in elderly patients, but they are associated with an increased risk of hypoglycaemia. Is sitagliptin a better choice? International Journal of Clinical Practice (Source: Medscape Today Headlines)
Source: Medscape Today Headlines - June 19, 2015 Category: Consumer Health News Tags: Diabetes & Endocrinology Journal Article Source Type: news